Hemophilia B Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Key Companies - Pfizer, Spark Therapeutics, Sanofi, Alnylam Pharmaceuticals, CSL Behring, uniQure, Novo Nordisk

DelveInsight's "Hemophilia B Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hemophilia B, historical and forecasted epidemiology as well as the Hemophilia B market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Hemophilia B market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hemophilia B Market Forecast
https://www.delveinsight.com/report-store/hemophilia-b-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Hemophilia B Market Report:
• The Hemophilia B market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• The total prevalent population of haemophilia B in the 7MM was 10,739 in 2020, and it is projected to increase by 2032
• France had the highest prevalence of haemophilia B among the five European nations in 2020, followed by the United Kingdom
• Key Hemophilia B Companies: Pfizer, Spark Therapeutics, Sanofi, Alnylam Pharmaceuticals, CSL Behring, uniQure, Novo Nordisk, Freeline Therapeutics, ApcinteX, Bioverativ Therapeutics Inc., Grifols Biologicals, LLC, Novo Nordisk A/S, Medexus Pharma, Inc., Wyeth, and others
• Key Hemophilia B Therapies: Marstacimab (PF-06741086), SPK-9001, Fitusiran, AMT-061, Concizumab, FLT180a, SerpinPC, rFIXFc, BeneFIX, Nonacog beta pegol, APVO101, rFIX, and others
• The Hemophilia B epidemiology based on severity-based cases analyzed that moderate and severe accounts for ~75% of the Hemophilia B patient pool
• The Hemophilia B market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hemophilia B pipeline products will significantly revolutionize the Hemophilia B market dynamics.

Hemophilia B Overview
People with haemophilia B, a rare inherited bleeding illness, have low quantities of the blood protein factor IX. The quantity of factor IX (FIX) in a person's blood determines the severity of their haemophilia.

Get a Free sample for the Hemophilia B Market Report
https://www.delveinsight.com/sample-request/hemophilia-b-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Hemophilia B Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Hemophilia B Epidemiology Segmentation:
The Hemophilia B market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Hemophilia B
• Prevalent Cases of Hemophilia B by severity
• Gender-specific Prevalence of Hemophilia B
• Diagnosed Cases of Episodic and Chronic Hemophilia B

Download the report to understand which factors are driving Hemophilia B epidemiology trends @ Hemophilia B Epidemiology Forecast
https://www.delveinsight.com/sample-request/hemophilia-b-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Hemophilia B Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hemophilia B market or expected to get launched during the study period. The analysis covers Hemophilia B market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Hemophilia B Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Hemophilia B Therapies and Key Companies
• Marstacimab (PF-06741086): Pfizer
• SPK-9001: Pfizer/Spark Therapeutics
• Fitusiran: Sanofi/ Alnylam Pharmaceuticals
• AMT-061: CSL Behring/ uniQure
• Concizumab: Novo Nordisk
• FLT180a: Freeline Therapeutics
• SerpinPC: ApcinteX

Discover more about therapies set to grab major Hemophilia B market share @ Hemophilia B Treatment Market
https://www.delveinsight.com/sample-request/hemophilia-b-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Hemophilia B Market Drivers
• Popularity of Gene Therapy
• Increased Focus on Prophylactic Treatment
• Development of Novel Treatments with extended half-life

Hemophilia B Market Barriers
• High Cost of Treatment
• Inconvenience and Scheduling Barriers
• Lack of Skilled Healthcare Professionals

Scope of the Hemophilia B Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Hemophilia B Companies: Pfizer, Spark Therapeutics, Sanofi, Alnylam Pharmaceuticals, CSL Behring, uniQure, Novo Nordisk, Freeline Therapeutics, ApcinteX, Bioverativ Therapeutics Inc., Grifols Biologicals, LLC, Novo Nordisk A/S, Medexus Pharma, Inc., Wyeth, and others
• Key Hemophilia B Therapies: Marstacimab (PF-06741086), SPK-9001, Fitusiran, AMT-061, Concizumab, FLT180a, SerpinPC, rFIXFc, BeneFIX, Nonacog beta pegol, APVO101, rFIX, and others
• Hemophilia B Therapeutic Assessment: Hemophilia B current marketed and Hemophilia B emerging therapies
• Hemophilia B Market Dynamics: Hemophilia B market drivers and Hemophilia B market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Hemophilia B Unmet Needs, KOL's views, Analyst's views, Hemophilia B Market Access and Reimbursement

To know more about Hemophilia B companies working in the treatment market, visit @ Hemophilia B Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/hemophilia-b-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Hemophilia B Market Report Introduction
2. Executive Summary for Hemophilia B
3. SWOT analysis of Hemophilia B
4. Hemophilia B Patient Share (%) Overview at a Glance
5. Hemophilia B Market Overview at a Glance
6. Hemophilia B Disease Background and Overview
7. Hemophilia B Epidemiology and Patient Population
8. Country-Specific Patient Population of Hemophilia B
9. Hemophilia B Current Treatment and Medical Practices
10. Hemophilia B Unmet Needs
11. Hemophilia B Emerging Therapies
12. Hemophilia B Market Outlook
13. Country-Wise Hemophilia B Market Analysis (2019-2032)
14. Hemophilia B Market Access and Reimbursement of Therapies
15. Hemophilia B Market Drivers
16. Hemophilia B Market Barriers
17. Hemophilia B Appendix
18. Hemophilia B Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:
Hemophilia B Pipeline
https://www.delveinsight.com/report-store/hemophilia-b-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Hemophilia B Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Hemophilia B market. A detailed picture of the Hemophilia B pipeline landscape is provided, which includes the disease overview and Hemophilia B treatment guidelines.
Hemophilia B Epidemiology https://www.delveinsight.com/report-store/hemophilia-b-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Hemophilia B Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Hemophilia B epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Scedosporium Infection Market https://www.delveinsight.com/report-store/scedosporium-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Scedosporium Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Scedosporium Infection, historical and forecasted epidemiology as well as the Scedosporium Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Vascular Graft Devices Market https://www.delveinsight.com/report-store/vascular-grafts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2027 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Vascular Stents Market https://www.delveinsight.com/report-store/vascular-stents-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2027 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Bladder Scanners Market https://www.delveinsight.com/report-store/bladder-scanners-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Recent Blog's By DelveInsight:

• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry
https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Media Contact

Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.